REG - IXICO plc - Result of AGM

IXICOAnnouncement

17/01/2020 16:35

RNS Number : 2251A
IXICO plc
17 January 2020
 


17 January 2020
 
IXICO plc
("IXICO" or the "Company")
 
Results of AGM
 
 
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, can announce that resolutions one to five were put forward to its Annual General Meeting held earlier today and were duly passed whilst resolution six was not duly passed. The votes cast at the meeting were as follows:
 



Resolution


Description


Total Votes For


% Votes


Total Votes Against


% Votes


Withheld


Votes cast as a % of ISC




1


Reports and Accounts


21,954,961


100.00%


200


0.00%


800


46.62




2


Re-election of Directors




























2a


Re-election of Giulio Cerroni


21,955,461


100.00%


500


0.00%


0


46.62




2b


Re-election of Grant Nash


21,955,461


100.00%


500


0.00%


0


46.62




3


Re-appointment of Auditors


21,949,261


99.99%


1,700


0.01%


5,000


46.61




4


Allotment of Securities


21,953,961


99.99%


1,700


0.01%


300


46.62




5


Disapply Pre-Emption Provisions


21,953,761


99.99%


1,900


0.01%


300


46.62




6


Amendment of Rule 3 of the Long-Term Incentive Plan


10,641,004


48.48%


11,309,157


51.52%


5,800


46.61



 
Charles Spicer, Chairman of the Board of IXICO, commented:
 
"The board notes the results of the resolution to approve the amendment to the IXICO LTIP and, over the coming months, will engage with those major shareholders who did not support this resolution to understand their concerns."
 



For further information please contact:
 



IXICO plc
Giulio Cerroni, Chief Executive Officer


 
+44 (0) 20 3763 7499




Grant Nash, Chief Financial Officer
 











Cenkos Securities PLC (Nominated adviser and sole broker)




Giles Balleny / Max Gould (Corporate Finance)




Michael F Johnson / Russell Kerr (Sales)






+44 (0) 20 7397 8900

















Optimum Strategic Communications




Mary Clark, Supriya Mathur, Manel Mateus




IXICO@optimumcomms.com






+44 (0) 203 950 9144






















 
 







About IXICO
 
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.
Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
More information is available on www.IXICO.com




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGKKOBNABKDBDD